← Back to patent-cliff list
萘普生钠/琥珀酸舒马普坦
Tier C — Watch / tradeNaproxen Sodium/Sumatriptan Succinate
Pernix Therapeutics Llc
Originator
2008
First approval
-
Expiry (public)
No sales data
Peak sales
化学药
Type
Targets：5-HT、COXs
Brand：Treximet、Suvexx
Indications (approved)：偏头痛
Regional status
US
批准上市
2008-04-15
EU
-
China
批准上市
2025-05-20
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Naproxen Sodium/Sumatriptan Succinate?
Approved indications include: 偏头痛.
When does the Naproxen Sodium/Sumatriptan Succinate patent expire?
No public expiry year is available for Naproxen Sodium/Sumatriptan Succinate yet; this page updates once verified.
How do I get a quote for Naproxen Sodium/Sumatriptan Succinate intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-24